Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.18
Price-6.17%
-$1.65
1Y
Price
Market Cap
$2.590b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-25513.9%
EBITDA Margin-25036.3%
Net Profit Margin-13981.6%
Free Cash Flow Margin-25513.9%
EBITDA Margin-25036.3%
Net Profit Margin-13981.6%
Free Cash Flow MarginRevenue
$156.035m
+11.7%
1y CAGR+16.2%
3y CAGR+142.1%
5y CAGREarnings
-$85.427m
-6.8%
1y CAGR-37.4%
3y CAGR-14.5%
5y CAGREPS
-$0.86
-6.2%
1y CAGR-30.0%
3y CAGR-7.9%
5y CAGRBook Value
$1.067b
$1.386b
Assets$319.193m
Liabilities$247.358m
DebtDebt to Assets
17.8%
-4.1x
Debt to EBITDAFree Cash Flow
-$372.768m
-3.5%
1y CAGR-33.1%
3y CAGR-172.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company